Hukumar Lafiya ta Duniya (WHO) ta sanar a yau cewa GlaxoSmithKline (GSK) za ta sabunta alkawarinta na ba da gudummawar maganin tsutsotsi na albendazole har sai an kawar da filariasis na lymphatic a duniya a matsayin matsalar lafiyar jama'a. Bugu da kari, a shekara ta 2025, za a ba da gudummawar allunan miliyan 200 a kowace shekara don maganin STH, kuma nan da 2025, allunan miliyan 5 a kowace shekara don maganin cystic echinococcosis.
Wannan sabuwar sanarwar ta ginu ne kan alkawurran da kamfanin ya yi na tsawon shekaru 23 na yaki da Cututtukan da ba a kula da su ba (NTDs) da ke yin illa ga wasu daga cikin mafiya talauci a duniya.
Waɗannan alkawuran wani bangare ne na alƙawarin ban sha'awa da GSK ta yi a yau a taron kolin cutar zazzabin cizon sauro da rashin kula da wuraren zafi da aka yi a Kigali, inda suka sanar da zuba jarin fan biliyan 1 cikin shekaru 10 don haɓaka ci gaba kan cututtuka masu yaduwa. - kasashen samun kudin shiga. Sanarwar manema labarai).
Binciken zai mayar da hankali ne kan sabbin magunguna da alluran rigakafi don rigakafi da magance cutar zazzabin cizon sauro, tarin fuka, HIV (ta hanyar ViiV Healthcare) da cututtukan da ba a kula da su ba, da magance juriya na rigakafin ƙwayoyin cuta, wanda ke ci gaba da shafar yawancin jama'a da ke haifar da mutuwar mutane da yawa. . Nauyin cututtuka a yawancin ƙasashe masu karamin karfi ya wuce 60%.